Literature DB >> 26194538

Platelet activation markers overexpressed specifically in patients with aspirin-exacerbated respiratory disease.

Chihiro Mitsui1, Keiichi Kajiwara2, Hiroaki Hayashi2, Jun Ito2, Haruhisa Mita2, Emiko Ono2, Noritaka Higashi3, Yuma Fukutomi2, Kiyoshi Sekiya2, Takahiro Tsuburai2, Kazuo Akiyama2, Kazuhiko Yamamoto4, Masami Taniguchi5.   

Abstract

BACKGROUND: Aspirin-exacerbated respiratory disease (AERD) is characterized by respiratory reactions on ingestion of COX-1 inhibitors and cysteinyl leukotriene overproduction. The hypersensitivity reaction is induced by low doses of aspirin that inhibit COX-1 in platelets.
OBJECTIVE: We sought to explore the role of platelets in the pathogenesis of AERD in patients under stable conditions and during an aspirin challenge test.
METHODS: Stable patients with AERD (n = 30), aspirin-tolerant asthma (ATA; n = 21), or idiopathic chronic eosinophilic pneumonia (n = 10) were enrolled. Platelet activation was estimated based on expression levels of P-selectin (CD62P), CD63, CD69, and GPIIb/IIIa (PAC-1) in peripheral platelets; percentages of circulating platelet-adherent leukocytes; and plasma levels of soluble P-selectin (sP-selectin) and soluble CD40 ligand (sCD40L).
RESULTS: In the stable condition, expression of all surface markers on platelets, the percentage of platelet-adherent eosinophils, and the plasma levels of sP-selectin and sCD40L were significantly higher in patients with AERD compared with those in patients with ATA. P-selectin and CD63 expression on platelets and plasma sP-selectin and sCD40L levels were positively correlated with the percentage of platelet-adherent eosinophils. Among these markers, P-selectin expression and plasma sP-selectin levels positively correlated with urinary concentrations of leukotriene E4. Additionally, plasma sP-selectin and sCD40L levels were negatively correlated with lung function. In contrast, platelet activation markers in patients with AERD did not change during the aspirin challenge test.
CONCLUSION: Peripheral platelets were activated more in patients with stable AERD compared with those in patients with stable ATA, patients with idiopathic chronic eosinophilic pneumonia, and control subjects. Platelet activation was involved in cysteinyl leukotriene overproduction and persistent airflow limitations in patients with AERD.
Copyright © 2015 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  P-selectin; adhesion; aspirin-exacerbated respiratory disease; asthma; cysteinyl leukotriene; platelet

Mesh:

Substances:

Year:  2015        PMID: 26194538     DOI: 10.1016/j.jaci.2015.05.041

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  24 in total

1.  Increased expression of L-plastin in nasal polyp of patients with nonsteroidal anti-inflammatory drug-exacerbated respiratory disease.

Authors:  Tetsuji Takabayashi; Yukie Tanaka; Dai Susuki; Kanako Yoshida; Kaori Tomita; Masafumi Sakashita; Yoshimasa Imoto; Yukinori Kato; Norihiko Narita; Tsugihisa Nakayama; Shinichi Haruna; Robert P Schleimer; Shigeharu Fujieda
Journal:  Allergy       Date:  2018-12-17       Impact factor: 13.146

Review 2.  Aspirin-Exacerbated Diseases: Advances in Asthma with Nasal Polyposis, Urticaria, Angioedema, and Anaphylaxis.

Authors:  Whitney Stevens; Kathleen Buchheit; Katherine N Cahill
Journal:  Curr Allergy Asthma Rep       Date:  2015-12       Impact factor: 4.806

3.  Increased thrombin-activatable fibrinolysis inhibitor levels in patients with chronic rhinosinusitis with nasal polyps.

Authors:  Yoshimasa Imoto; Atsushi Kato; Tetsuji Takabayashi; Whitney Stevens; James E Norton; Lydia A Suh; Roderick G Carter; Ava R Weibman; Kathryn E Hulse; Kathleen E Harris; Anju T Peters; Leslie C Grammer; Bruce K Tan; Kevin Welch; Stephanie Shintani-Smith; David B Conley; Robert C Kern; Shigeharu Fujieda; Robert P Schleimer
Journal:  J Allergy Clin Immunol       Date:  2019-09-25       Impact factor: 10.793

4.  Microparticles in nasal lavage fluids in chronic rhinosinusitis: Potential biomarkers for diagnosis of aspirin-exacerbated respiratory disease.

Authors:  Toru Takahashi; Atsushi Kato; Sergejs Berdnikovs; Whitney W Stevens; Lydia A Suh; James E Norton; Roderick G Carter; Kathleen E Harris; Anju T Peters; Kathryn E Hulse; Leslie C Grammer; Kevin C Welch; Stephanie Shintani-Smith; Bruce K Tan; David B Conley; Robert C Kern; Bruce S Bochner; Robert P Schleimer
Journal:  J Allergy Clin Immunol       Date:  2017-02-24       Impact factor: 10.793

Review 5.  Formation of nasal polyps: The roles of innate type 2 inflammation and deposition of fibrin.

Authors:  Tetsuji Takabayashi; Robert P Schleimer
Journal:  J Allergy Clin Immunol       Date:  2020-03       Impact factor: 10.793

6.  Plasma P-Selectin Is Inversely Associated with Lung Function and Corticosteroid Responsiveness in Asthma.

Authors:  Mats W Johansson; Brandon M Grill; Karina T Barretto; Molly C Favour; Hazel M Schira; Calvin M Swanson; Kristine E Lee; Ronald L Sorkness; Deane F Mosher; Loren C Denlinger; Nizar N Jarjour
Journal:  Int Arch Allergy Immunol       Date:  2020-08-10       Impact factor: 2.749

7.  Unique Effect of Aspirin Therapy on Biomarkers in Aspirin-exacerbated Respiratory Disease. A Prospective Trial.

Authors:  Katherine N Cahill; Jing Cui; Parul Kothari; Katherine Murphy; Benjamin A Raby; Joseph Singer; Elliot Israel; Joshua A Boyce; Tanya M Laidlaw
Journal:  Am J Respir Crit Care Med       Date:  2019-09-15       Impact factor: 21.405

8.  Inflammatory heterogeneity in aspirin-exacerbated respiratory disease.

Authors:  William C Scott; Katherine N Cahill; Ginger L Milne; Ping Li; Quanhu Sheng; Li Ching Huang; Spencer Dennis; Jacob Snyder; Ashley M Bauer; Rakesh K Chandra; Naweed I Chowdhury; Justin H Turner
Journal:  J Allergy Clin Immunol       Date:  2020-11-12       Impact factor: 10.793

9.  A trial of type 12 purinergic (P2Y12) receptor inhibition with prasugrel identifies a potentially distinct endotype of patients with aspirin-exacerbated respiratory disease.

Authors:  Tanya M Laidlaw; Katherine N Cahill; Juan Carlos Cardet; Katherine Murphy; Jing Cui; Brittney Dioneda; Parul Kothari; Benjamin A Raby; Elliot Israel; Joshua A Boyce
Journal:  J Allergy Clin Immunol       Date:  2018-06-08       Impact factor: 10.793

10.  The blocking effect of the glycoprotein IIb/IIIa receptor in the mouse model of asthma.

Authors:  Seo-Hee Kim; Hoang Kim Tu Trinh; Hae-Sim Park; Yoo Seob Shin
Journal:  Clin Mol Allergy       Date:  2021-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.